Home > Journals > Giornale Italiano di Dermatologia e Venereologia > Past Issues > Giornale Italiano di Dermatologia e Venereologia 2018 February;153(1) > Giornale Italiano di Dermatologia e Venereologia 2018 February;153(1):95-101

CURRENT ISSUE
 

ARTICLE TOOLS

Publication history
Reprints
Cite this article as

GIORNALE ITALIANO DI DERMATOLOGIA E VENEREOLOGIA

A Journal on Dermatology and Sexually Transmitted Diseases


Official Journal of the Italian Society of Dermatology and Sexually Transmitted Diseases
Indexed/Abstracted in: EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 1,311


eTOC

 

REVIEW  


Giornale Italiano di Dermatologia e Venereologia 2018 February;153(1):95-101

DOI: 10.23736/S0392-0488.17.05794-7

Copyright © 2017 EDIZIONI MINERVA MEDICA

language: English

Atopic dermatitis treatment: what’s new on the horizon?

Fabrizio PANARESE 1, 2, Matteo AURIEMMA 2, Angelo CARBONE 3, Paolo AMERIO 1, 2

1 CESI Institute, University of Chieti-Pescara, Chieti, Italy; 2 Department of Dermatology, University of Chieti-Pescara, Chieti, Italy; 3 ”L’immacolata” Clinic, University of the Sacred Heart of Rome, Celano, L’Aquila, Italy


PDF  


Atopic dermatitis (AD) is an inflammatory disorder of the skin characterized by an impaired immune response and skin barrier function. It is very frequent in adult population being present in up to 10% of population. Quality of life is often reduced in AD patients due to disease burden and symptoms like itch. AD is also frequently associated with psychological diseases such as anxiety or depression. Due to its chronic nature and severity of presentation AD often may not respond to topical treatment and requires systemic treatments which can be associated with significant side effects. A Medline search of the last five years with the keywords “Atopic dermatitis” and “treatment” was performed. Moreover a search throughout the clinicaltrial.gov webpage was performed with the keyword AD. Several topical and systemic treatments are being studied in randomized controlled trials or in case series or in pivotal studies. The progression of the insight on AD pathogenesis have made possible to target single molecules responsible for key aspect of the development of this disease. We discuss the various molecules (small anti-inflammatory molecules, monoclonal antibodies against cytokines) that will be hopefully soon available for the treatment of this disease which still carries an important burden of unmet needs for its treatment.


KEY WORDS: Dermatitis, atopic - Therapeutics - Review

top of page

Publication History

Issue published online: January 8, 2018
Manuscript accepted: October 16, 2017
Manuscript received: September 30, 2017

Cite this article as

Panarese F, Auriemma M, Carbone A, Amerio P. Atopic dermatitis treatment: what’s new on the horizon. G Ital Dermatol Venereol 2018;153:95-101. DOI: 10.23736/S0392-0488.17.05794-7

Corresponding author e-mail

p.amerio@unich.it